ALPEGA-GROUP
Alpega, a global leader in logistics SaaS software, announces its recognition as a Challenger in the 2024 Gartner Magic Quadrant for Transportation Management Systems (TMS). We believe this acknowledgment underscores Alpega’s unwavering commitment to delivering cutting-edge solutions tailored to meet the evolving demands of the transportation industry. The Gartner report evaluates vendors based on their completeness of vision and ability to execute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417652913/en/
(Photo: Alpega)
Alpega serves global customers with deployments in all geographies, addressing diverse sectors such as automotive, retail, fast-moving consumer goods, and manufacturing, Alpega places significant emphasis on fostering collaboration with carriers, optimizing transportation procurement, and championing environmental, social, and governance (ESG) initiatives.
Backed by a history of exceptional customer retention rates and proactive engagement, Alpega pledges unparalleled support and satisfaction. As the company continues to expand its business, it remains steadfast in its commitment to deliver creative solutions to the problems remaining in the transportation space, solidifying its status as a trusted partner in the ever-evolving domain of logistics. We invite you to learn more about our recognition by accessing the complete Gartner Magic Quadrant report [here].
Alpega CEO, Todd DeLaughter, remarked, “As we celebrate our recognition as a Challenger in the 2024 Gartner Magic Quadrant, we reaffirm our commitment to pushing the boundaries of innovation and excellence in transportation management technology. With a customer-centric ethos and an unyielding drive for progress, we are poised to lead the industry towards a future defined by efficiency, sustainability, unparalleled service and most importantly, unlocking business value for our customers.”
Gartner subscribers can access the complete Magic Quadrant for Transportation Management Systems here Gartner Disclaimer.
Recognized as Alpega Group from 2020 to 2024 and as inet-logistics from 2011 to 2019.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Alpega
Alpega is a leading global logistics SaaS software company committed to providing comprehensive end-to-end solutions that cater to all transport requirements. Our overarching mission is to enable shippers and carriers to navigate today's logistics challenges efficiently through digitalization, thereby driving smarter logistics for a greener tomorrow
Harnessing the extensive assets of our carrier network, Alpega delivers tangible benefits across Execution, Planning, Sourcing, and Payment solutions. As the premier SaaS provider offering Transport Management Systems (TMS) for shippers, alongside an 80,000-strong open carrier network covering approximately 10% of all commercial trucks in Europe, we stand at the forefront of innovation and efficiency. For carriers, our connectivity spans three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and South-eastern European regions, facilitating seamless matching of freight loads with transportation capacity.
With over three decades of transportation expertise, we empower businesses to streamline their supply chain planning and execution, resulting in reduced costs and enhanced visibility. Alpega's suite of solutions synergistically creates added value for our customers. Our community comprises 80,000 carriers and 200,000 members, electronically interconnected each day to efficiently manage vital transport operations. Operating in 80 countries worldwide, Alpega boasts a diverse team of over 500 professionals representing 31 nationalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417652913/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom